ABO Blood Group and Risk of Pancreatic Carcinogenesis in Intraductal Papillary Mucinous Neoplasms
Open Access
- 2 March 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 30 (5), 1020-1028
- https://doi.org/10.1158/1055-9965.epi-20-1581
Abstract
Background: ABO blood group has been associated with risks of various malignancies, including pancreatic cancer. No study has evaluated the association of ABO blood group with incidence of pancreatic carcinogenesis during follow-up of patients with intraductal papillary mucinous neoplasms (IPMN). Methods: Among 3,164 patients diagnosed with pancreatic cysts at the University of Tokyo (Tokyo, Japan) from 1994 through 2019, we identified 1,815 patients with IPMN with available data on ABO blood group. We studied the association of ABO blood group with incidence of pancreatic carcinoma, overall and by carcinoma types [IPMN-derived carcinoma or concomitant pancreatic ductal adenocarcinoma (PDAC)]. Utilizing competing-risks proportional hazards models, we estimated subdistribution hazard ratios (SHR) for incidence of pancreatic carcinoma with adjustment for potential confounders, including cyst characteristics. Results: During 11,518 person-years of follow-up, we identified 97 patients diagnosed with pancreatic carcinoma (53 with IPMN-derived carcinoma and 44 with concomitant PDAC). Compared with patients with blood group O, patients with blood groups A, B, and AB had multivariable SHRs (95% confidence intervals) for pancreatic carcinoma of 2.25 (1.25–4.07; P = 0.007), 2.09 (1.08–4.05; P = 0.028), and 1.17 (0.43–3.19; P = 0.76), respectively. We observed no differential association of ABO blood group with pancreatic carcinoma incidence by carcinoma types. Conclusions: In this large long-term study, patients with IPMN with blood group A or B appeared to be at higher risk of pancreatic carcinoma compared with those with blood group O. Impact: ABO blood group can be a biomarker for pancreatic cancer risk among patients with IPMNs.Funding Information
- Japan Society for the Promotion of Science (JP19K08362)
This publication has 57 references indexed in Scilit:
- An Absolute Risk Model to Identify Individuals at Elevated Risk for Pancreatic Cancer in the General PopulationPLOS ONE, 2013
- ABO Blood Group and Risk of Pancreatic Cancer: A Study in Shanghai and Meta-AnalysisAmerican Journal of Epidemiology, 2013
- ABO Research in the Modern Era of GenomicsTransfusion Medicine Reviews, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerThe New England Journal of Medicine, 2011
- Variant ABO Blood Group Alleles, Secretor Status, and Risk of Pancreatic Cancer: Results from the Pancreatic Cancer Cohort ConsortiumCancer Epidemiology, Biomarkers & Prevention, 2010
- Pancreatic Cancer Risk and ABO Blood Group Alleles: Results from the Pancreatic Cancer Cohort ConsortiumCancer Research, 2010
- Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancerNature Genetics, 2009
- ABO Blood Group and the Risk of Pancreatic CancerJNCI Journal of the National Cancer Institute, 2009
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- The distribution of the ABO blood groups in JapanJournal of Human Genetics, 1978